Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän

Immunity and Vaccine Deve… - Göteborgs universitet Till startsida
Till innehåll Läs mer om hur kakor används på gu.se

Immunity and Vaccine Development Against Helicobacter pylori

Kapitel i bok
Författare A. K. Walduck
Sukanya Raghavan
Publicerad i Advances in experimental medicine and biology
Sidor 257-275
ISBN 978-3-030-21915-4
ISSN 0065-2598
Förlag Springer
Publiceringsår 2019
Publicerad vid Institutionen för biomedicin, avdelningen för mikrobiologi och immunologi
Sidor 257-275
Språk en
Länkar dx.doi.org/10.1007/5584_2019_370
Ämnesord Gastritis, Helicobacter pylori, Immunity, Regulatory T cell, Vaccine, bacterial vaccine, animal, Helicobacter infection, human, immunology, microbiology, Animals, Bacterial Vaccines, Helicobacter Infections, Humans
Ämneskategorier Immunologi inom det medicinska området, Mikrobiologi inom det medicinska området


Helicobacter pylori is a highly-adapted gastrointestinal pathogen of humans and the immunology of this chronic infection is extremely complex. Despite the availability of antibiotic therapy, the global incidence of H. pylori infection remains high, particularly in low to middle-income nations. Failure of therapy and the spread of antibiotic resistance among the bacteria are significant problems and provide impetus for the development of new therapies and vaccines to treat or prevent gastric ulcer, and gastric carcinoma. The expansion of knowledge on gastric conventional and regulatory T cell responses, and the role of TH17 in chronic gastritis from studies in mouse models and patients have provided valuable insights into how gastritis is initiated and maintained. The development of human challenge models for testing candidate vaccines has meant a unique opportunity to study acute infection, but the field of vaccine development has not progressed as rapidly as anticipated. One clear lesson learned from previous studies is that we need a better understanding of the immune suppressive mechanisms in vivo to be able to design vaccine strategies. There is still an urgent need to identify practical surrogate markers of protection that could be deployed in future field vaccine trials. Important developments in our understanding of the chronic inflammatory response, progress and problems arising from human studies, and an outlook for the future of clinical vaccine trials will be discussed.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?